Albany, New York, November 30, 2016: A latest market research on the Systematic Lupus Erythematosus disease has been released by Global Markets Direct. This analysis has been added to the market intelligence repository of Market Research Hub (MRH). The report is titled as “Systemic Lupus Erythematosus – Pipeline Review, H2 2016”, and it offers an overview on the key pipeline products in the global systemic lupus erythematosus market. The study report also features investigational drugs from across the globe covering over 20 therapy areas and nearly 3,000 indications.
Request for Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=873439
The guide covers the descriptive pharmacological action of the therapeutics, its complete research & development history along with latest news and press releases obtained from company/university sites and industry specific third party resources. Furthermore, it covers emerging therapies for systemic lupus erythematosus in active clinical development stages including early and late stage clinical trials.
Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory disorder. This can affect skin, joints, kidneys, brain and other organs. SLE is more common in women than men and can occur at any age. However, it appears most frequently in people between the ages of 15 and 44. The disease affects African Americans and Asians more often than people from other races. Till now, no cure has been observed for SLE. The main goal of the treatment is to control its symptoms. Symptoms can vary and can change over time. Some common symptoms include-
- severe fatigue
- painful or swollen joints
- butterfly rash (ash on cheeks and nose)
- hair loss
The mild treatment includes the use of Corticosteroid creams for skin rashes, Hydroxychloroquine drug (i.e. also used to treat malaria), Belimumab; a biologic drug. Treatments for more severe SLE may include:
- High-dose corticosteroids.
- Immunosuppressive drugs (drugs which suppress the immune system).
- Blood thinners, such as Coumadin for clotting disorders.
Browse Full Info with TOC: http://www.marketresearchhub.com/report/systemic-lupus-erythematosus-pipeline-review-h2-2016-report.html
Drug profiles featured in the report go through periodic review resulting to a stringent set of methods to confirm that all the profiles are updated with the latest set of information. Also, the report reviews key players in the industry, involved in the therapeutics development for systemic lupus erythematous and enlists all their major & minor projects. Through this market review, the buyer will be able to develop tactical initiatives. They can also create in-licensing and out-licensing strategies by recognizing prospective partners with the attractive projects to enhance and expand business potential and scope.
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.